Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog – Page 5

Get the latest international news and world events from around the world.

Log in for authorized contributors

Rivian CEO Exposes Legacy Automaker EV Lies

Rivian CEO RJ Scaringe claims that legacy automakers are intentionally slowing down electric vehicle adoption and hindering competition to protect their profits from gas-powered vehicles, which could threaten their survival and allow newer EV makers like Rivian and Tesla to dominate the market ## ## Questions to inspire discussion.

Legacy Automakers and EVs.

🚗 Q: Why are legacy automakers resistant to selling EVs? A: Legacy automakers don’t want to sell EVs because they make good margins on low-efficiency gas cars and can sell them at a premium price, preferring to see the EV market disappear.

đŸ›ïž Q: How are legacy automakers fighting against EV policies? A: Legacy automakers are the biggest adversaries of EV policies, spending the most energy fighting against them in DC, reflecting their desire for the EV market to vanish. Rivian’s Challenges and Strategy.

💰 Q: What financial challenge does Rivian face? A: Rivian has a massive $23 billion debt, making it more indebted than any startup has ever been, requiring 10–20 years to become cash flow positive.

đŸ›» Q: How is Rivian addressing its product pricing? A: Rivian’s R2 electric truck, launching in 2025, will target a **$45,000 starting price, a strategic move to make their products more accessible.

Continue reading “Rivian CEO Exposes Legacy Automaker EV Lies” | >

The Dawn of Tesla’s Robotaxi Network & Automated Transportation

Tesla’s launch of a robo-taxi network marks the beginning of a significant transportation disruption that will transform mobility, economy, geopolitics, and urban landscapes with the widespread adoption of electric autonomous vehicles ## ## Questions to inspire discussion.

Transportation Revolution.

🚗 Q: How will Tesla’s Robotaxi network impact transportation? A: Tesla’s Robotaxi network in Austin, Texas marks the ignition point for transportation disruption, with multiple companies competing to provide taxi rides without human drivers, potentially capturing 80–90% market share in 10–15 years.

đŸ›ąïž Q: What industries will be disrupted by autonomous electric vehicles? A: Autonomous electric vehicles will disrupt the oil and agriculture industries, as vehicles are the number one users of crude oil, and corn is the top agricultural product in the US, used to produce ethanol for gasoline.

🌆 Q: How will urban planning change with the rise of autonomous vehicles? A: Cities will repurpose parking spaces for retail, living areas, and solar panels, transforming urban planning and enabling new forms of transportation, including drones and aircraft.

Environmental Impact.

Continue reading “The Dawn of Tesla’s Robotaxi Network & Automated Transportation” | >

Largest review of antidepressants to date finds most people do not experience severe withdrawal

The largest review of “gold standard” antidepressant withdrawal studies to date has identified the type and incidence of symptoms experienced by people discontinuing antidepressants, finding most people do not experience severe withdrawal.

“Incidence and Nature of Antidepressant Discontinuation Symptoms, A Systematic Review and Meta-analysis” was published in JAMA Psychiatry.

In a and meta-analysis of previous randomized controlled trials relating to antidepressant withdrawal, a team of researchers led by Imperial College London and King’s College London concluded that, while participants who stopped antidepressants did experience an average of one more symptom than those who continued or were taking placebos, this was not enough to be judged as significant.

Dark matter could create dark dwarfs at the center of the Milky Way

Dark matter is one of nature’s most confounding mysteries. It keeps particle physicists up at night and cosmologists glued to their supercomputer simulations. We know it’s real because its mass prevents galaxies from falling apart. But we don’t know what it is.

Dark matter doesn’t like other matter and may prefer its own company. While it doesn’t seem to interact with regular baryonic matter, it could possibly react with itself and self-annihilate. It needs a tightly-packed environment to do that, and that may lead to a way astrophysicists can finally detect it.

New theoretical research outlines how this could happen and states that sub-stellar objects, basically , could host the process. The research is titled “Dark dwarfs: -powered sub-stellar objects awaiting discovery at the ,” and it’s published in the Journal of Cosmology and Astroparticle Physics. The lead author is Djuna Croon, a and assistant professor in the Institute for Particle Physics Phenomenology in the Department of Physics at Durham University.

Machines learn like us!

In recent years, with the public availability of AI tools, more people have become aware of how closely the inner workings of artificial intelligence can resemble those of a human brain.

There are several similarities in how machines and human brains work, for example, in how they represent the world in abstract form, generalise from limited data, and process data in layers. A new paper in Nature Communications is adding another feature to the list: Convexity.

“We found that convexity is surprisingly common in deep networks and might be a fundamental property that emerges naturally as machines learn,” says the senior author.

Plasma proteomics links brain and immune system aging with healthspan and longevity

In a large-scale proteomic study of biological aging of 11 organs from 44,498 individuals in the UK Biobank, the biological ages of the brain and immune system emerged as strong predictors of healthspan and longevity.

Multiomics and cellular senescence profiling of aging human skeletal muscle uncovers Maraviroc as a senotherapeutic approach for sarcopenia

This study leverages single-nucleus multiomics to map cellular senescence atlas in aging human skeletal muscle and uncovers potential targets and senotherapeutics for treating age-associated sarcopenia.